End-stage renal disease (ESRD) is a growing global health problem with major health and economic implications. Cardiovascular complication is the major cause of morbidity and mortality in this population. Clustering of traditional atherosclerotic risk factors, such as diabetes, systemic inflammation, and altered mineral metabolism, contributes to enhanced systemic atherosclerosis in patients with ESRD. Prevalence of obstructive coronary artery disease (CAD) on coronary angiography exceeds 50% in this population. Despite having extensive CAD and vascular disease, patients with ESRD often do not present with classic symptoms because of impaired exercise capacity and diabetes. Furthermore, clinical trial data are exceedingly lacking in this population, resulting in considerable clinical equipoise regarding the optimal approach to the identification and subsequent management of CAD in these patients. Traditional clinical screening tools, including conventional risk prediction models, are significantly limited in their predictive accuracy for cardiovascular events in patients with ESRD. Noninvasive cardiac stress imaging modalities, such as nuclear perfusion and echocardiography, have been shown to improve the traditional clinical model in identifying the presence of CAD. Furthermore, they add incremental prognostic information to angiographic data. Novel imaging techniques and biomarker assays hold significant promise in further improving the ability to identify and risk-stratify for CAD. This review focuses on the current understanding of the clinical risk profile of asymptomatic patients with ESRD with an emphasis on the strengths and limitations of various noninvasive cardiovascular imaging modalities, including the role of novel methods in refining risk prediction. In addition, issues and challenges pertaining to the optimal timing of initial risk assessment ("screening") and possible repeat screening ("surveillance") are addressed. We also summarize the current data on the approach to the patient with ESRD being evaluated for transplantation in the context of recent guidelines and position statements by various professional societies. (J Am Coll Cardiol Img 2014;7:715-28)
GRACE (Global Registry of Acute Coronary
Events) showed that patients with ESRD had 3-fold higher in-hospital and long-term mortality and MI compared with the population not receiving dialysis (6) . Renal dysfunction also is a well-known prognostic factor after coronary artery bypass grafting.
Patients with renal replacement therapy undergoing coronary artery bypass grafting have a high operative and long-term mortality (7) . Patients with ESRD form the highest-risk group with adverse cardiac outcomes, and CAD screening/risk stratification thus assumes paramount importance. However, traditional atherosclerotic risk factors, including diabetes, hypertension, and dyslipidemia, are significantly more prevalent in patients with ESRD, but they only partially explain the increased risk for CAD and coronary events (8) , thereby significantly limiting the predictive ability of traditional risk estimate tools.
Furthermore, the Framingham risk score, the most well-validated CAD risk prediction tool, does not incorporate renal function (9) . Pooled analyses from large epidemiologic studies have demonstrated poor predictive accuracy of the Framingham risk model in cardiovascular risk prediction in patients with chronic kidney disease (CKD), underestimating risk by as much as 50% (10) .
SERUM BIOMARKERS FOR RISK ASSESSMENT
The limited predictive accuracy of traditional risk prediction instruments in the population with renal failure has led to an extensive search for "novel" risk factors, including the role of various biomarkers to help refine risk assessment. These include markers of myocardial injury, systemic inflammation, endothelial dysfunction, sympathetic overactivation, oxidative stress, and vascular atherosclerosis. These novel markers are significantly more prevalent in patients with ESRD, in whom they seem to have a stronger association with cardiovascular events compared with patients without ESRD (11) .
Among the wide array of extensively studied biomarkers, the cardiac troponin assay seems to be most promising. Troponin T is an extremely sensitive indicator of myocardial necrosis. A meta-analysis from 28 prospective studies involving approximately 4,000 patients with ESRD with no symptoms found that a positive troponin T level (>0.1 ng/ml) was a major predictor for increased all-cause mortality (relative risk: 2.64) and cardiac death (relative risk:
2.55) when adjusted for age, diabetes, left ventricular hypertrophy (LVH), and depressed left ventricular (LV) function (12) .
In a small study, positive troponin T in patients with ESRD with no symptoms at the initiation of dialytic therapy was found to predict coronary stenosis on coronary angiography (sensitivity: 92%; specificity: 64%; area under the curve: 0.77) (13) . Although biomarkers do predict events, they are limited by their lack of specificity. The specificity of troponin is limited because it is elevated in more than one-third of patients with ESRD (likely related to LVH, hypertension/hypotension, and silent ischemia).
Furthermore, in the presence of other promising biomarkers, selecting the best 1 or combination thereof for refining risk prediction and integrating into part of a systematic approach for the management of patients with ESRD will require welldesigned prospective trials.
CHALLENGES OF CAD SCREENING IN PATIENTS WITH ESRD AND CARDIAC

STRESS IMAGING
A large proportion of the population with ESRD cannot exercise because of frequent noncardiac One-quarter of all deaths in the population with ESRD is thought to be due to sudden cardiac death (20, 21 of them to high risk (9.8% annualized cardiac mortality) (37) .
Therefore, the potential role of coronary flow reserve quantification may reside in risk-stratifying patients without overt regional perfusion defects with other imaging modalities and could be used to test medical therapy that could improve vasomotor function. In the general population, a calcium score of 0 is rarely seen in patients with significant coronary stenosis. Absence of calcium has a high (>95%) negative predictive value for significant angiographic coronary stenosis in symptomatic patients with a high pre-test likelihood of CAD (50) . Some data also exist for CACS as a predictor of future cardiac events in the population with ESRD (51-54) ( Table 2 CTA. A multicenter study showed that CTA performed well in detecting/excluding coronary stenosis when compared with invasive angiography. Overall, the positive predictive value was moderate, but the negative predictive value was high (>98%) (59) . In addition to its diagnostic ability, a large amount of outcome data have also validated its prognostic value. In particular, those subjects with no evidence of CAD on CTA had excellent short-to intermediateterm prognosis (60) .
E C H O C A R D I O G R A P H Y -B A S E D A S S E S S M E
Limited data exist evaluating the role of CTA in patients with ESRD (61, 62) . One small study using a
16-slice multidetector CT system in 19 patients
showed that 14% of vessels could not be evaluated.
Compared with invasive angiography, the sensitivity, specificity, and positive and negative predictive values of CTA for a diagnosis of >50% stenosis were 86%, 81%, 78%, and 88%, respectively (61). Another small study (N ¼ 29) using 64-slice CTA showed that 36% of patients with ESRD actually had a zero to low CACS, making major obstructive CAD unlikely.
Although the overall correlation between high CACS and obstructive disease was good, a significant number of patients with CACS between 400 and 2,000 had <70% stenosis, with many having <50% disease by CTA in the major coronary arteries (62) . Hakeem et al.
of patients with <70% coronary artery stenosis had a cardiac event compared with those with >70% stenosis (71).
In a large study of 3,698 patients who were referred for MPS as part of renal transplant evaluation, significant CAD (>50% stenosis) was found in 62% of 260 patients who underwent invasive angiography (33% with 3-vessel disease). After a mean follow-up of 30 AE 15 months, depressed LVEF, myocardial perfusion defects on MPS, diabetes, and age >45 years were all predictors of worse outcome, whereas degree of angiographic CAD was not. In addition, revascularization improved survival only in the subset of patients with 3-vessel disease without previous coronary artery bypass graft surgery but not in others (72) . Similar results were reported in a cohort of 222 patients (73) . There was no apparent survival difference between patients who underwent angiography and patients who did not. Therefore, on the basis of these findings, routine invasive angiography before transplant is not recommended.
NONINVASIVE CARDIAC STRESS IMAGING. Several studies examined the "diagnostic performance" of MPS and DSE using coronary luminal stenosis on invasive angiography as the endpoint (defined as luminal narrowing >50% in any epicardial vessel).
The sensitivity of MPS ranged from 29% to 100%, and specificity ranged from 31% to 88% (74) (75) (76) (77) . Stressinduced WMA on DSE had a sensitivity of 44% to 96% and a specificity of 60% to 100% (70, (78) (79) (80) (81) (82) (83) (84) (95% confidence interval: 1.1 to 4.4) for mortality (88) . More important, the functional information derived from MPS or DSE was a more powerful predictor of outcomes than the purely anatomic information from angiography (72, 89, 90) . 
GUIDELINES
